This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $300 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoLive In-Person Event: December 4 - 8, 2022

Charles Craik, Ph.D.
Professor in the Departments of Pharmaceutical Chemistry, Cellular & Molecular Pharmacology and Biochemistry & Biophysics at University of California at San Francisco


Charles Craik is a Professor in the Department of Pharmaceutical Chemistry at the University of California at San Francisco. He is the founder and former director of the Chemistry and Chemical Biology Graduate Program and is an Associate Director in the Helen Diller Family Comprehensive Cancer Center. He received his education and training in Chemistry at Allegheny College (BS), Columbia University (Ph.D.) and UCSF (Postdoctoral). Since joining the UCSF faculty his research interests have focused on defining the roles and the mechanisms of enzymes, protein degradation machinery, receptors, membrane transporters and other challenging proteins in complex biological processes and on developing technologies to facilitate these studies. These studies coupled with his global substrate profiling, antibody engineering and noninvasive imaging efforts are providing a better understanding of both the chemical make-up and the biological importance of these critical proteins to aid in the rapid detection, monitoring and control of infectious disease, neurological disorders and cancer.  Craik is a council member of the American Association of Biochemistry and Molecular Biology (ASBMB), a Fellow of the American Association for the Advancement of Science (AAAS) and the National Academy of Inventors (NAI) and a member of the American Academy of Arts and Sciences.

Agenda Sessions

  • Targeting Challenging Protein Targets Using Conformationally Selective Antibodies